8th Microbiome Movement Drug Development Summit
The 8th Microbiome Movement Drug Development Summit returns in 2023 as North America’s definitive microbiome drug development event – and it’s back bigger and better than ever!
The microbiome-based therapeutic market is rapidly evolving, and it’s more important than ever to showcase the efficacy of microbial-based approaches beyond C. difficile. Discover how drug developers are advancing their understanding of the role of the microbiome in disease and harnessing functionally relevant microbes for live biotherapeutic approaches.
Join us, as we provide in-depth insights into the interactions between the microbiome and metabolic pathways, host-microbe relationships in novel preclinical models, and the application of microbial-based biomarkers in clinical endpoints and diagnostic settings. Our sessions also cover the mechanistic rationale behind combination therapies, new smart clinical trial data, and GMP compliant manufacturing for stable products.
With more speakers, content, and networking than ever before, this is set to be the best version of the event yet and you cannot afford to miss it!
Time: 8:30 am – 5:40 pm
Venue details: Omni Boston Hotel at the Seaport, 450 Summer Street, Boston, Massachusetts, 02210, United States
Prices:
Pharma and Biotech Pricing: Conference + Workshop Day: USD 3296.00,
Pharma and Biotech Pricing: Conference + Focus Day: USD 3296.00,
Pharma and Biotech Pricing: Conference Only: USD 2099.00,
Solution and Service Provider Pricing: Conference + Pre-Conference Focus Day: USD 4396.00,
Solution and Service Provider Pricing: Conference + Pre-Conference Workshop Day: USD 4396.00,
Solution and Service Provider Pricing: Conference Only: USD 2899.00,
Academic, Not-For-Profit Provider and Start-Up Pricing: Conference + Workshop Day: USD 2396.00,
Academic, Not-For-Profit Provider and Start-Up Pricing: Conference + Focus Day: USD 2396.00,
Academic, Not-For-Profit Provider and Start-Up Pricing: Conference Only: USD 1499.00
Speakers: Aaron Cowley, Chief Scientific Officer, Arranta Bio, Alicia Szretter, Associate Director, Vedanta Biosciences Inc, Brett Noel, Innovation Lead, Sanofi, Kyle Jacoby, Vice President – Biology, Federation Bio, Michelle Rooks, Associate Fellow – Research, Pfizer, Paul Carlson, Principal Investigator, FDA, Rebecca Senter, Vice President, Head of Preclinical Research and Development, Axial Therapeutics, Inc., Robert Brucker, Co-founder and Chief Scientific Officer, DermBiont, Samantha Coulson, Head of Clinical Research, Servatus ltd., Yvonne Nyavor, Principal Scientist, Boston Analytical, Trevor Lawley, Chief Scientific Officer and Founder, Microbiotica, Travis Whitfill, Chief Operating Officer, Azitra Inc., Tariq Warsi, Vice President Technical Operations, Novome Biotechnologies , and many more